Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809588 · ClinicalTrials.gov registry record · Phase 1
Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT00809588 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 84 participants.
The verdict
NCT00809588, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the proposed therapy will delay or stop the progression of the participants skin cancer. This study is being done because there are currently no treatments which have been shown convincing to treat disease which has progressed. This research study is designed to evaluate the immunologic effects and clinical side effects of giving vaccines to patients that are made from their own skin cancer cells.
Interventions
- BIOLOGICAL Autologous, lethally irradiated melanoma cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2003-10-16 |
| Est. Completion | 2020-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809588
The ClinicalTrials.gov registry entry for NCT00809588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous, lethally irradiated melanoma cells is the first listed.
NCT00809588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809588 about?
NCT00809588 is a clinical study titled "Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)". The purpose of this study is to see if the proposed therapy will delay or stop the progression of the participants skin cancer. This study is being done because there are currently no treatments which have been shown convincing to treat disease which has progressed. This research study is designed t...
What is the current status of trial NCT00809588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2003-10-16. Estimated completion is 2020-02-25.
What interventions are being tested in trial NCT00809588?
The interventions under investigation include: Autologous, lethally irradiated melanoma cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00809588?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.